AGL and urinary bladder carcinoma: Another study found that hyaluronic acid 2 (HAS2) is the driver of tumour growth of bladder cancer with low AGL, suggesting a preclinical rational for personalised targeting in patients with low AGL expressing bladder tumours [126].